title: Abatacept in difficult-to-treat juvenile idiopathic arthritis.
abstract: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and an important cause of short-term and long-term disability. Gene changes in the immune system can predispose to JIA and regulation of the immune system is crucial in the pathogenesis. The goal of therapy is complete disease control using disease-modifying antirheumatic drugs (DMARDS). Activated T-cells may play a role in the immunopathology of JIA. Therefore, targeting T-cell activation is a rational approach for the treatment of JIA. Abatacept (ABA), a selective co-stimulation modulator, has been shown to be effective in treating all JIA subtypes and is generally safe and well tolerated in JIA. Neutralizing antibodies were found in 6/9 (67%) of seropositive patients, but anti-ABA antibodies did not appear to be associated with disease flare, serious adverse events, acute infusional adverse events, hypersensitivity, autoimmune disorders, or low ABA serum concentrations. Anti-ABA antibodies were more frequent when ABA concentrations were below therapeutic levels. Although information on ABA in JIA is still limited, available data suggest a potential role in difficult to treat JIA patients previously treated with other biologic agents and for non-responders to TNF-blockade.
authors.affiliation: Pediatric Rheumatology Clinics, Dept of Pediatrics, University Hospital Tübingen, Germany;
authors.forename: Jasmin B
authors.initials: JB
authors.lastname: Kuemmerle-Deschner
authors.forename: Sm
authors.initials: S
authors.lastname: Benseler
references.citation: J Rheumatol. 2004 Feb;31(2):390-2
references.pmid: 14760812
references.citation: J Immunol. 2004 May 15;172(10):6435-43
references.pmid: 15128835
references.citation: Rheumatology (Oxford). 2007 Feb;46(2):308-13
references.pmid: 16877460
references.citation: J Rheumatol Suppl. 1992 Apr;33:6-10
references.pmid: 1593604
references.citation: J Rheumatol. 2002 May;29(5):1058-64
references.pmid: 12022323
references.citation: Rheumatol Int. 2005 Apr;25(3):169-78
references.pmid: 15688190
references.citation: Curr Rheumatol Rep. 2006 Dec;8(6):450-8
references.pmid: 17092444
references.citation: Arthritis Rheum. 2006 Sep;54(9):2807-16
references.pmid: 16947384
references.citation: Arthritis Rheum. 2005 Mar;52(3):818-25
references.pmid: 15751095
references.citation: Science. 1994 Aug 26;265(5176):1225-7
references.pmid: 7520604
references.citation: Arthritis Rheum. 2007 Nov;56(11):3793-804
references.pmid: 17968951
references.citation: Arthritis Rheum. 2002 Oct;46(10):2721-9
references.pmid: 12384932
references.citation: J Immunol. 1998 Sep 15;161(6):2762-71
references.pmid: 9743334
references.citation: Ann Rheum Dis. 2008 Apr;67(4):547-54
references.pmid: 17921185
references.citation: Pediatrics. 2002 Jan;109(1):109-15
references.pmid: 11773549
references.citation: Lancet. 2007 Mar 3;369(9563):767-778
references.pmid: 17336654
references.citation: Ann Rheum Dis. 2007 Feb;66(2):228-34
references.pmid: 16935912
references.citation: Pediatr Clin North Am. 1995 Oct;42(5):1099-125
references.pmid: 7567188
references.citation: Nat Clin Pract Rheumatol. 2007 Jul;3(7):382-90
references.pmid: 17599072
references.citation: Nat Rev Drug Discov. 2003 Jun;2(6):473-88
references.pmid: 12776222
references.citation: Arthritis Res Ther. 2005;7(2):R241-9
references.pmid: 15743470
references.citation: JAMA. 2005 Oct 5;294(13):1671-84
references.pmid: 16204667
references.citation: J Exp Med. 1999 Mar 15;189(6):969-78
references.pmid: 10075980
references.citation: Arthritis Rheum. 2003 May;48(5):1398-407
references.pmid: 12746913
references.citation: Eur J Immunol. 1996 Oct;26(10):2320-8
references.pmid: 8898940
references.citation: Arch Dis Child. 2003 Mar;88(3):186-91
references.pmid: 12598373
references.citation: J Rheumatol. 2005 May;32(5):935-42
references.pmid: 15868633
references.citation: J Clin Invest. 1999 May;103(9):1243-52
references.pmid: 10225967
references.citation: Clin Exp Rheumatol. 1999 May-Jun;17(3):367-74
references.pmid: 10410275
references.citation: Z Rheumatol. 2008 Mar;67(2):111-6, 118-20
references.pmid: 18309499
references.citation: Arthritis Rheum. 2004 Sep;50(9):2920-30
references.pmid: 15457461
references.citation: Lancet. 2008 Aug 2;372(9636):383-91
references.pmid: 18632147
references.citation: Rheum Dis Clin North Am. 1991 Nov;17(4):891-905
references.pmid: 1767079
references.citation: N Engl J Med. 2003 Nov 13;349(20):1907-15
references.pmid: 14614165
references.citation: Arthritis Res Ther. 2005;7(6):R1281-8
references.pmid: 16277681
references.citation: Ann Intern Med. 2006 Jun 20;144(12):865-76
references.pmid: 16785475
references.citation: Arthritis Res Ther. 2005;7(2):R256-67
references.pmid: 15743472
references.citation: J Exp Med. 1993 Nov 1;178(5):1801-6
references.pmid: 8228826
references.citation: N Engl J Med. 2005 Apr 21;352(16):1655-66
references.pmid: 15843668
references.citation: Ann Rheum Dis. 2006 Oct;65(10):1351-6
references.pmid: 16504994
references.citation: J Rheumatol. 2000 Sep;27(9):2256-63
references.pmid: 10990244
references.citation: Arthritis Rheum. 2002 Jun;46(6):1470-9
references.pmid: 12115176
references.citation: J Clin Invest. 1998 Oct 1;102(7):1369-76
references.pmid: 9769329
references.citation: Ann Rheum Dis. 2008 Mar;67(3):302-8
references.pmid: 17947302
references.citation: J Endocrinol. 2007 Jun;193(3):323-30
references.pmid: 17535871
references.citation: J Rheumatol. 2006 Dec;33(12):2398-408
references.pmid: 17225293